1. Home
  2. TAP vs BMRN Comparison

TAP vs BMRN Comparison

Compare TAP & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Molson Coors Beverage Company Class B

TAP

Molson Coors Beverage Company Class B

HOLD

Current Price

$54.37

Market Cap

10.1B

ML Signal

HOLD

Logo BioMarin Pharmaceutical Inc.

BMRN

BioMarin Pharmaceutical Inc.

HOLD

Current Price

$59.97

Market Cap

10.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAP
BMRN
Founded
1873
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1B
10.0B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
TAP
BMRN
Price
$54.37
$59.97
Analyst Decision
Hold
Buy
Analyst Count
15
21
Target Price
$51.67
$89.86
AVG Volume (30 Days)
2.7M
2.0M
Earning Date
02-18-2026
02-20-2026
Dividend Yield
3.53%
N/A
EPS Growth
N/A
59.53
EPS
N/A
2.68
Revenue
$11,214,000,000.00
$3,094,001,000.00
Revenue This Year
N/A
$13.53
Revenue Next Year
N/A
$9.69
P/E Ratio
N/A
$22.50
Revenue Growth
N/A
12.39
52 Week Low
$42.94
$50.76
52 Week High
$64.66
$73.51

Technical Indicators

Market Signals
Indicator
TAP
BMRN
Relative Strength Index (RSI) 72.45 61.73
Support Level $50.65 $56.87
Resistance Level $50.70 $58.43
Average True Range (ATR) 1.35 1.73
MACD 0.44 0.33
Stochastic Oscillator 93.57 76.61

Price Performance

Historical Comparison
TAP
BMRN

About TAP Molson Coors Beverage Company Class B

Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the US, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the US, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.

About BMRN BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Share on Social Networks: